Significantly increases serum concentration of drugs like warfarin, phenytoin, and sulfonylureas.

Fungicidal activity is observed only at very high concentrations against some species.

Resistance to Diflucan is a growing concern, particularly with Candida glabrata and krusei.

Can cause a rare but severe cutaneous reaction like Stevens-Johnson syndrome.

Therapeutic success relies heavily on host immune status and source control.

Not reliably effective in fungal endocarditis, where fungicidal therapy is preferred.

Can be used in some pediatric fungal infections with appropriate weight-based dosing.

Diflucan can be used for prolonged periods in certain endemic mycoses.

Plays a role in selective digestive decontamination protocols in some ICU settings.

Diflucan exposure is a major risk factor for the development of azole-resistant candidiasis.